These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 16798086)

  • 1. Stop-codon read-through for patients affected by a lysosomal storage disorder.
    Brooks DA; Muller VJ; Hopwood JJ
    Trends Mol Med; 2006 Aug; 12(8):367-73. PubMed ID: 16798086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients.
    Hein LK; Bawden M; Muller VJ; Sillence D; Hopwood JJ; Brooks DA
    J Mol Biol; 2004 Apr; 338(3):453-62. PubMed ID: 15081804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy.
    Howard MT; Shirts BH; Petros LM; Flanigan KM; Gesteland RF; Atkins JF
    Ann Neurol; 2000 Aug; 48(2):164-9. PubMed ID: 10939566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy for lysosomal storage disorders.
    Beck M
    IUBMB Life; 2010 Jan; 62(1):33-40. PubMed ID: 20014233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy.
    Malik V; Rodino-Klapac LR; Viollet L; Wall C; King W; Al-Dahhak R; Lewis S; Shilling CJ; Kota J; Serrano-Munuera C; Hayes J; Mahan JD; Campbell KJ; Banwell B; Dasouki M; Watts V; Sivakumar K; Bien-Willner R; Flanigan KM; Sahenk Z; Barohn RJ; Walker CM; Mendell JR
    Ann Neurol; 2010 Jun; 67(6):771-80. PubMed ID: 20517938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system.
    Keeling KM; Bedwell DM
    J Mol Med (Berl); 2002 Jun; 80(6):367-76. PubMed ID: 12072912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of a methylmalonyl-CoA mutase stopcodon mutation.
    Buck NE; Wood LR; Hamilton NJ; Bennett MJ; Peters HL
    Biochem Biophys Res Commun; 2012 Nov; 427(4):753-7. PubMed ID: 23041189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current therapeutic strategies in lysosomal disorders].
    Kaminsky P; Lidove O
    Presse Med; 2014 Nov; 43(11):1174-84. PubMed ID: 24863660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment.
    Bidou L; Hatin I; Perez N; Allamand V; Panthier JJ; Rousset JP
    Gene Ther; 2004 Apr; 11(7):619-27. PubMed ID: 14973546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of gentamicin inducing readthrough premature stop Codons: A study of alpha-L-iduronidase nonsense variants in COS-7 Cells.
    Ngiwsara L; Sawangareetrakul P; Wattanasirichaigoon D; Tim-Aroon T; Dejkhamron P; Champattanachai V; Ketudat-Cairns JR; Svasti J
    Biochem Biophys Res Commun; 2022 Dec; 636(Pt 1):147-154. PubMed ID: 36332477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation.
    Keeling KM; Brooks DA; Hopwood JJ; Li P; Thompson JN; Bedwell DM
    Hum Mol Genet; 2001 Feb; 10(3):291-9. PubMed ID: 11159948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current strategies in the management of lysosomal storage diseases.
    Heese BA
    Semin Pediatr Neurol; 2008 Sep; 15(3):119-26. PubMed ID: 18708002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Aminoglycoside and Non-Aminoglycoside Compounds for Stop-Codon Readthrough Therapy in Four Lysosomal Storage Diseases.
    Gómez-Grau M; Garrido E; Cozar M; Rodriguez-Sureda V; Domínguez C; Arenas C; Gatti RA; Cormand B; Grinberg D; Vilageliu L
    PLoS One; 2015; 10(8):e0135873. PubMed ID: 26287674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lysosomes and lysosomal storage diseases].
    Germain DP
    J Soc Biol; 2002; 196(2):127-34. PubMed ID: 12360741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy for the lysosomal storage disorders.
    Cabrera-Salazar MA; Novelli E; Barranger JA
    Curr Opin Mol Ther; 2002 Aug; 4(4):349-58. PubMed ID: 12222873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease.
    Hemsley KM; Luck AJ; Crawley AC; Hassiotis S; Beard H; King B; Rozek T; Rozaklis T; Fuller M; Hopwood JJ
    Eur J Neurosci; 2009 Mar; 29(6):1197-214. PubMed ID: 19302155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatments for lysosomal storage disorders.
    Lachmann R
    Biochem Soc Trans; 2010 Dec; 38(6):1465-8. PubMed ID: 21118108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and emerging therapies for the lysosomal storage disorders.
    Pastores GM; Barnett NL
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):891-902. PubMed ID: 16262569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of heterozygous nonsense mutations in genes of interest using an Escherichia coli-based stop codon assay.
    Moon YJ; Kang Y; Choi JH; Lee KH
    Biotechnol Appl Biochem; 2007 Feb; 46(Pt 2):137-43. PubMed ID: 16995837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme replacement and enhancement therapies: lessons from lysosomal disorders.
    Desnick RJ; Schuchman EH
    Nat Rev Genet; 2002 Dec; 3(12):954-66. PubMed ID: 12459725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.